![]() ![]() ![]() There was a significant between-group difference in the magnitude of reduction in NLC episodes ( p = 0.01), indicating a higher decrease in the MOMH group as compared to the placebo group (− 3.4 vs − 2.6, respectively). The number of NLC episodes has significantly decreased by the end of the study period as compared to baseline in both groups ( p < 0.001 for both). Resultsġ75 (81%) out of 216 initially screened subjects completed the study. ANCOVA followed by contrast analysis was used for comparison of groups at the end of the study. The Student’s test or Mann-Whitney test were used for between-group comparison at different timepoints. ![]() The Fisher’s Exact Test for comparison of groups by categorical variables was used. The assessed parameters included frequency and duration of NLC episodes, quality of sleep, NLC-induced pain and quality of life sub-scores. Eligible subjects received a capsule with MOMH 226 mg or placebo, once daily, at bedtime, for a 60-day period. MethodsĪ randomized, double-blind, placebo-controlled multicenter study was conducted in hospitals and outpatient clinics in Ukraine, from February to August 2018. In the current study, we tested the efficacy and safety of a magnesium supplement – magnesium oxide monohydrate (MOMH), for which increased cellular absorption rates were demonstrated in an ex-vivo setting. The main impediment stems from the lack of assessments of cellular absorption. However, there is little evidence in support of their effectiveness. Magnesium supplements are widely used for prophylaxis and treatment of nocturnal leg cramps (NLC). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |